3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
108
Endometrial Neoplasms
16
Polycystic Ovary Syndrome
9
Neoplasm Metastasis
9
Ovarian Neoplasms
7
Neoplasms
7
Advanced Breast Cancer
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Recurrence
3
Infertility
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Squamous Cell Carcinoma of Head and Neck
2
Progesterone Resistance
2
Neoplasms by Site
2
Hereditary Sensory and Autonomic Neuropathies
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Hyperplasia
2
Cystadenocarcinoma, Serous
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Breast Cancer Metastatic
2
Breast Cancer Female
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
Fulvestrant
3
Letrozole
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
ribociclib
1
pegfilgrastim
1
exemestane
1
abemaciclib
1
Zoledronic Acid
1
Tamoxifen
1
Paclitaxel
1
Neoadjuvant Therapy
1
Gemcitabine
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Cancer Metastatic
×
Letrozole
×
1 year
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts
NCT04603183
2025-12-12
ABIGAIL
MedSIR
Phase 2
Completed
162 enrolled